Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. Studies show that people who receive early treatment for RA feel better sooner and more often, and are more likely to lead an active life. They also are less likely to have the type of joint damage that leads to joint replacement. At ACR Convergence 2020, a vast repository of new research related to RA was presented to participants. To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, reviewed the abstracts and presents her picks for the top research in RA.
Rheumatologists have many new treatments that target the inflammation that RA causes. When and how to use one new treatment to get the best effects was the focus of The Great Debate at ACR Convergence 2020: Janus Kinase Inhibitors Should/Should Not Be Used Before Biologics After Methotrexate Failure in RA. No need to hang in suspense. In this resource center, you’ll get the pros and cons described by the expert presenters of this session, and highlights from other important sessions on RA at ACR Convergence 2020 selected by Physician Editor Philip Seo, MD, MHS.
Plus, you can explore The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of RA.